Clinical Trial

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To learn if belzutifan can help to control the disease in patients with metastatic RCC who are considered candidates for active surveillance and have not undergone previous systemic treatment. The safety of belzutifan in this patient population will also be studied.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-10.
Status change: Not Yet Recruiting → Recruiting 2026-05-19
Trial Details
NCT Number NCT07023432
Lead Sponsor M.D. Anderson Cancer Center
Conditions Active Surveillance, Clear Cell Renal Cell Carcinoma
Enrollment 78 participants
Start Date 2025-11-17
Primary Completion 2028-04-14 (estimated)
Study Completion 2030-04-14 (estimated)
Updated on ClinicalTrials.gov 2026-05-22